Theodore Feld Reiss MD
Critical Care Medicine, Pleural Disease
Professor, Medicine, Vanderbilt University School of Medicine
Join to View Full Profile
1161 21st Ave South T-1218 Medical Center NorthVanderbilt University School Of MedicineNashville, TN 37232
Phone+1 615-322-3773
Fax+1 615-343-7448
Dr. Reiss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Residency, Neurological Surgery, 1992 - 1995- University of California (San Francisco)Fellowship, Pulmonary Disease and Critical Care Medicine, 1986 - 1989
Vanderbilt University Medical CenterResidency, Internal Medicine, 1983 - 1984
Vanderbilt University School of MedicineClass of 1983
Certifications & Licensure
NJ State Medical License 1991 - 2025
TN State Medical License 2011 - 2013
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- 27 citationsCC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial.Zoran Popmihajlov, Donna J Sutherland, Gerald S Horan, Atalanta Ghosh, David A Lynch
BMJ Open Respiratory Research. 2022-01-01 - 1 citationsPilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma Exacerbations.Donald H. Arnold, Sara L. Van Driest, Theodore F. Reiss, Jennifer C King, Wendell S Akers
Journal of Clinical Pharmacology. 2021-03-01 - 2 citationsAdverse events associated with weight-based, high-dose montelukast exposures in children.Donald H. Arnold, Nena Bowman, Theodore F Reiss, Tina V. Hartert, Wendell S Akers
Clinical Toxicology. 2020-02-01
Press Mentions
Chutes & Ladders—Repertoire Immune Medicines, Buzzing from $189M Series B, Taps Celgene Vet as CMOJune 4th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
